Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibikase TherapeuticsIKT 35 3-Year EBITDA Growth Rate is 49.80% as of Jun. 2026. GuruFocus rates IKT with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,125 Biotechnology companies, Inhibikase Therapeutics ranks better than 85.51% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 49.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Inhibikase Therapeutics was 49.80% per year. The lowest was -56.50% per year. And the median was -8.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Inhibikase Therapeutics 3-Year EBITDA Growth Rate Related Terms
IKT vs ABEO, STRO, AGEN: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Inhibikase Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 49.80% mean?
Inhibikase Therapeutics (IKT) has a 3-Year EBITDA Growth Rate of 49.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Inhibikase Therapeutics and its competitors. According to the industry distribution chart, Inhibikase Therapeutics ranks #163 out of 1125 companies in the Biotechnology industry, placing it in the top 14.5%.
Is Inhibikase Therapeutics' 3-Year EBITDA Growth Rate too high?
Inhibikase Therapeutics' current 3-Year EBITDA Growth Rate is 49.80%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Inhibikase Therapeutics' value of 49.80% is 238.8% above this industry median. Based on the distribution chart, Inhibikase Therapeutics ranks #163 out of 1125 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inhibikase Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' 3-Year EBITDA Growth Rate compare to ABEO and STRO?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #163 out of 1125 companies for 3-Year EBITDA Growth Rate. This places Inhibikase Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Inhibikase Therapeutics' value of 49.80% is 238.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,125 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhibikase Therapeutics's current 3-Year EBITDA Growth Rate of 49.80% is 238.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Inhibikase Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibikase Therapeutics's current 3-Year EBITDA Growth Rate is 49.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current 3-Year EBITDA Growth Rate of 49.80%. The current 3-Year EBITDA Growth Rate is 49.80% and 238.8% above the Biotechnology industry median of 14.70. Inhibikase Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current 3-Year EBITDA Growth Rate is 49.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
35GF Score
Get the complete analysis for IKT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
